Case study

01 Feb 2021

Diabetic Foot Ulcer Case Study


Overview

TFS was selected by this small European biotech company to develop provide full service support during the development of their genetically modified bacteria producing human proteins for improving wound healing. This ongoing study is a phase 1/2a study investigating the topical efficacy of the investigational medicinal product (IMP).

The phase 1 part is a multi-centre, open-label, non-randomized, uncontrolled dose-finding study. Each cycle of treatment lasted 2 weeks with 3 administrations of IMP per week on alternate days. Treatment cycles were sequentially administered, without treatment breaks. The actual treatment duration with IMP depended on the level of healing during treatment and was to be discontinued once the target ulcer was completely closed or when 3 cycles of treatment were completed (6 weeks of treatment). Extension of treatment beyond 3 cycles (6 weeks) was allowed on a case-by-case basis for maximum of additional 2 cycles (4 weeks).


    Challenges

    Germany

    • Very high Investigator Fees
    • Sites’ interest low due to study complexity – specific sites searched (having phase 1 unit & capacity/experience to deal with IMP)
    • Late changes to exploratory objectives, requiring retrospective data collection close to DBL
    • Regulatory challenges – close contact with competent authority (CA) necessary
    • Crucial for client to deliver Top Line Results according to agreed and communicated timelines

    Poland

    • Complex and long registration process for Genetic Engineering Unit (GEU) – close contact with authorities (Ministry of Environment) and sites
    • Sites identification was difficult due to study complexity – specific sites searched (having phase 1 unit & capacity/experience to deal with IMP)

    See Other Case Studies

    TFS involved in European global customer’s pre-lau...

    TFS was requested to prepare and conduct a Late Phase global proposal to support the pre-launch activities of two pro...

    Read more

    How TFS Strategic Resourcing Solutions deployed a ...

    Given the catastrophic spread of COVID-19, the search for safe and effective therapies has taken on an unpreced...

    Read more

    TFS & a Global Biotech Company

    As clinical trials grow increasingly complex, timelines shorten, and R&D costs soar. Today’s biopharmaceuti...

    Read more